Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2009

View Archived Issues

New venlafaxine prodrugs for depression imparted by Solvay

CrystaX scientists claim Hsp90 inhibitors and their use in cancer therapy

Sanofi-aventis presents novel PKB inhibitors for cancer

Novel PARP inhibitors under development at Abbott for the treatment of cancer

Indeglitazar, a pan-agonist of PPARs, entering phase II trial for type 2 diabetes mellitus

Gel and intravaginal ring forms of IQP-0528 are being developed as topical HIV microbicides

EMEA accepts for review Genmab's Arzerra NDA

MannKind updates NDA submission status for Afresa

RegeneRx provides update on phase II RGN-137 trial in venous stasis

Theravance receives FDA complete response letter for telavancin NDA

Cephalon intends to make a cash takeover offer to Arana

DSMB recommends continuation of phase III clinical trial of GTx's toremifene

MedImmune licenses biologics drug for treating asthma from La Jolla

Serenity completes phase II clinical trial of CPEX Pharmaceuticals' urology drug

MabThera approved in the E.U. for patients with chronic lymphocytic leukemia

AstraZeneca receives FDA complete response letter for Seroquel XR sNDA

Somaxon receives FDA complete response letter for Silenor

Phase II study shows potential benefit of erlotinib before cystectomy for bladder cancer

AZD-0530 inhibits cell growth and migration in human bladder cancer in vitro

Astellas commences tender offer to acquire outstanding shares of CV Therapeutics

Nitec completes recruitment in phase III Lodotra trial in rheumatoid arthritis

FDA approves Symbicort for chronic obstructive pulmonary disease

The Medicines Company acquires Targanta Therapeutics

Pharmaxis submits NDA to FDA for Aridol

Salix receives FDA complete response letter for Metozolv ODT

Abbott claims new Aurora kinase inhibitors as oncolytic agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 21, 2026
Psychedelic space expanding on Trump’s EO
BioWorld
Timothy Leary is dead, but he could be on the outside looking in with a smile on his face as U.S. President Donald Trump’s latest executive order (EO) fuels a...
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...